Harneys advises on completion of US$910 million business combination

Harneys recently acted as legal counsel to Maxpro Capital Acquisition Corp in a business combination with late-stage clinical biopharmaceutical company, Apollomics Inc. through a reverse merger. Apollomics’ Class A ordinary shares and public warrants commenced trading on 30 March 2023, on the Nasdaq Capital Market under the symbols "APLM" and "APLMW," respectively. Apollomics agreed to acquire Maxpro from MP One Investment LLC and others for approximately US$910 million in September 2022, pending shareholder approval.

Apollomics’ mission is to improve treatment options for patients diagnosed with difficult-to-treat, high-mortality cancers. The financing raised in connection with the Business Combination provides access to capital that is expected to enable Apollomics to advance its pipeline of drug candidates. The Harneys team was led by BVI-based Partner George Weston im with support from Associate Melissa Thomas. Harneys acted on instructions from US firm Nelson Mullins.

George commented: “We are delighted to have acted as legal counsel to Maxpro Capital Acquisition Corp. as it expands its business and becomes a publicly traded company. This transaction shows our capabilities advising on complex deals, particularly in the healthcare sector."

The Corporate team at Harneys excels at complex cross-border transactions involving BVI, Cayman Islands, Luxembourg and Cyprus vehicles. The firm’s significant track record includes complex mega-deals, high value private equity transactions, landmark IPOs and the full spectrum of public and private M&A and joint ventures. The firm's experienced SPAC practice group provides with Cayman and BVI incorporated vehicles with the full spectrum of legal advice and fiduciary services from incorporation, through to listing, business combination and beyond.